Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc > Don’t get your hopes high!

<< Previous

Bullboard Posts

Next >>

Post by Enzolinion Feb 11, 2021 1:07pm

163 Views

Post# 32542046

Don’t get your hopes high!

Do you guys really think this company has anything to help with Covid or all the others that were listed, love to believe that they had something but we need to remember history just hope it doesn't repeat itself. Also if they had anything with any hope with COVID we would hear about it in the news especially during this time, Robert will keep telling you what you want to hear.

<< Previous

Bullboard Posts

Next >>

Abcourt Mines launches Flordin property drill campaign